Cryo Cell International Inc: Form 10-Q for the period ended May 31, 2022
Filed with the SEC on Jul 11, 2022 and accepted by EDGAR at Jul 11, 2022, 21:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-03-01 to 2022-05-31 | $7.6m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2021-12-01 to 2022-05-31 | $14.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2022-03-01 to 2022-05-31 | $2.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-12-01 to 2022-05-31 | $4.3m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2022-03-01 to 2022-05-31 | $80.9k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-12-01 to 2022-05-31 | $228.1k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-03-01 to 2022-05-31 | $3.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2021-12-01 to 2022-05-31 | $7.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-03-01 to 2022-05-31 | $1.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-12-01 to 2022-05-31 | $2.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-03-01 to 2022-05-31 | $276.5k | us-gaap:InterestExpense |
| Interest expense | 6 months2021-12-01 to 2022-05-31 | $582.6k | us-gaap:InterestExpense |
| Income tax | 3 months2022-03-01 to 2022-05-31 | $265.1k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-12-01 to 2022-05-31 | $588.7k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-03-01 to 2022-05-31 | $634.7k | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-12-01 to 2022-05-31 | $1.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-03-01 to 2022-05-31 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-12-01 to 2022-05-31 | $0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-03-01 to 2022-05-31 | $0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-12-01 to 2022-05-31 | $0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-03-01 to 2022-05-31 | 8,553,085 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-12-01 to 2022-05-31 | 8,643,106 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-12-01 to 2022-05-31 | $3.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-12-01 to 2022-05-31 | $954.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2021-12-01 to 2022-05-31 | $1.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-05-31 | $2.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-05-31 | $10.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-05-31 | $55.4m | us-gaap:Assets |
| Current liabilities | At period end2022-05-31 | $15.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-05-31 | $51.0m | us-gaap:Liabilities |
| Long-term debt | At period end2022-05-31 | $357.8k | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-05-31 | $4.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-22-012605. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.